Send PM
Followers 445
Posts 27161
Boards Moderated 2
Alias Born 09/11/2006

Re: None

Monday, 08/18/2008 1:43:40 PM

Monday, August 18, 2008 1:43:40 PM

Post# of 35
Genomic Health Reliant on One Drug
Monday August 11, 12:25 pm ET
By Grant Zeng, CFA

Genomic Health Inc.'s (NasdaqGM: GHDX - News) lead product is Oncotype DX, which is used for early stage breast cancer patients to predict the likelihood of cancer recurrence. The company is also conducting studies to expand the product offering of Oncotype DX for patients with colorectal cancer. Sales of Oncotype remain robust. We maintain our Hold rating on the stock with a price target of $25.00.

On August 5, the company announced its second quarter results where total revenue increased to $27.8 million compared to $14.7 million in the second quarter of 2007. It also exceeded our estimate of $24.9 million. Net loss was $4.1 million in the second quarter of 2008, compared to $7.2 million in the second quarter of 2007. Our estimate of net loss was $6.2 million.

We are optimistic about the growth of Oncotype. Clinical studies have validated the use of Oncotype. In recent months, Oncotype met the criteria set by Blue Cross and Blue Shield Association Technology Evaluation Center for women with breast cancer and its use in breast cancer treatment selection was recommended by the American Society of Oncology.

The company relies heavily on Oncotype DX for both short-term and long-term growth. We would like to gain more visibility on how Genomic Health diversifies its product offerings and how it expands internationally before we become bullish on the shares.

surf's up......crikey

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y

Branded Legacy, Inc. Signs Joint Venture To Add Additional $300,000 a Year In Revenue BLEG Nov 23, 2022 11:10 AM

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial CMND Nov 23, 2022 9:50 AM

Branded Legacy, Inc. Gets Approval From State to Reduce Authorized Common Shares by 300 Million BLEG Nov 22, 2022 1:15 PM

Defiance Resumes Drilling In Zacatecas DNCVF Nov 22, 2022 11:53 AM

InnerScope Hearing Technologies (OTC: INND) Announces its HearingAssist Brand of OTC Hearing Aids on INND Nov 22, 2022 11:52 AM

ECRID Offers Federal Housing Finance Agency (FHFA) Credit & Lending Platform to Immediately Assist Low-Credit and No-Credit Home Buyers, and Others ECDD Nov 22, 2022 11:51 AM

BioLife Sciences Inc. (OTC:PK BLFE) is Pleased to Announce Its Q1 2023 Slated Release of Its Copper-Infused Fabric Pot Prototype BLFE Nov 22, 2022 11:50 AM

Fission 3.0 Hits Off-Scale Radioactivity in New Discovery on PLN A1 Conductor FUU Nov 21, 2022 11:05 AM

Perpetual Industries Reports Strong Third-Quarter PRPI Nov 21, 2022 8:00 AM

Nextech AR Solutions Corp. Reports Record Q3 Sequential Growth As 3D Modeling Revenue Surges +192% and Gross Profit Margin Improves To +60% NEXCF Nov 17, 2022 7:03 PM

AgriFORCE Receives Notice of Allowance Related to its FORCEGH+ Facility from the United States Patent and Trademark Office AGRIW Nov 17, 2022 9:06 AM

Organicell Starts Enrolling Long COVID Trial OCEL Nov 17, 2022 8:38 AM

Mullen Announces Funding to Close on ELMS Assets MULN Nov 17, 2022 8:30 AM

Maison Luxe Reports Revenues of Approximately $3.7 Million for the Quarter Ended September 30, 2022 as Compared to Approximately $2.7 Million for the Quarter Ended September 30, 2021, an increase of over 35% MASN Nov 17, 2022 8:19 AM

SKYX Wins Consumer Electronics Show (CES) 2023 Innovation Award for Smart Home Category for Smart Sky Ceiling Plug SKYX Nov 17, 2022 8:07 AM